ClinicalTrials.gg

Program

nisotirostide

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity, led by Eli Lilly.

Furthest: phase 2, since Mar 25, 20254 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly41 open or runningphase 2since Mar 25, 2025Nov 20, 2020May 2027phase 2 · NCT06897475
  • Named in Eli Lilly’s own pipeline as Nisotirostide, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2020First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT04641312 · 67 enrolled · Germany
  2. May 16, 2022Phase 1 study in Diabetes Mellitus, Type 2NCT05377333 · 94 enrolled · United States
  3. Oct 13, 2022Phase 1 study in OverweightNCT05582096 · 38 enrolled · United States
  4. Mar 25, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT06897475 · 200 planned · United States, Canada, Germany and more

Ahead

  1. May 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT06897475

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06897475Diabetes Mellitus, Type 2 · United States, Canada, Germany and more2RecruitingMay 2027200
NCT05582096Overweight · United States1CompletedJun 8, 202338
NCT05377333Diabetes Mellitus, Type 2 · United States1CompletedNov 22, 202394
NCT04641312Diabetes Mellitus, Type 2 · Germany1CompletedDec 21, 202167

How it is read

Names in the registry

  • “LY3457263”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.